NCT03330821 - Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 18, 2018

Primary Completion Date

October 13, 2025

Study Completion Date

October 16, 2026

Conditions

Acute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeAcute Myeloid Leukemia With Myelodysplasia-Related ChangesTherapy-Related Acute Myeloid Leukemia

Interventions

DRUG

Cytarabine

Given IV

DRUG

Idarubicin

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Pevonedistat

Given IV

OTHER

Pharmacological Study

Correlative studies

Trial Locations (5)

33136

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

44195

Cleveland Clinic, Cleveland

85724

University of Arizona Cancer Center - North Campus, Tucson

90033

Los Angeles County-USC Medical Center, Los Angeles

USC / Norris Comprehensive Cancer Center, Los Angeles

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER